Clinical benefits of two different dosing schedules of recombinant human erythropoietin in anemic patients with advanced head and neck cancer

BioScience Trends

Volumn 4, Issue 5, 2010, Pages 267-272

  Gupta, Seema ^a   Singh, Pankaj K ^a   Bhatt, Madan L B ^a   Pant, Mohan C ^a   Sundar, Sham ^a   Verma, Jiterndra ^a   Paul, Syan ^a   Kumar, Divesh ^a   Shah, Afsana ^a   Gupta, Rajeev ^a   Negi, Mahendra P S ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anemia; Epoetin beta; Head and neck cancer; Hemoglobin; Quality of life (QOL); Recombinant human erythropoietin

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; HEAD AND NECK TUMOR; HUMAN; MIDDLE AGED; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; IRON; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79951966958     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999; 80:827-841.
2. Carvalho AL, Salvajoli JV, Kowalski LP. A comparison of radiotherapy or chemotherapy with a symptomatic treatment alone in advanced head and neck carcinomas. Eur Arch Otorhinolaryngol. 2000; 257:164-167.
3. Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, Wahid I, Turkan S, Tatsuzaki H, Dinshaw KA, Overgaard J. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: Results of the IAEA multicentrerandomized trial. Radiother Oncol. 2003; 67:17-26.
4. Vikram B. Cancers of the head and neck region in developing countries. Radiother Oncol. 2003; 67:1-2.
5. Kumar S. National palliative care policy for India. Ind J Pall Care. 2000; 6:62.
6. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin α therapy. Cancer. 2002; 95:888-895.
7. Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin α treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003; 21:366-373.
8. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer. 2001; 91:2214-2221.
9. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002; 20:4083-4107.
10. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - cancer and treatment related anemia. Version 2, Jenkintown, PA, USA, 2004.
11. Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F; Canadian Eprex Oncology Study Group. Epoetin α therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are not receiving chemotherapy. J Clin Oncol. 2001; 19:4126-4134.
12. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ Jr, Glaspy J. Benefits of epoetin α in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002; 3:45-51.
13. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of onceweekly dosing of epoetin α in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19:2875-2882.
14. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003; 98:1072-1079.
15. Henry DH. The evolving role of epoetin α in cancer therapy. Oncologist. 2004; 9:97-107.
16. Cheer SM, Wagstaff AJ. Epoetin β: A review of its clinical use in the treatment of anemia in patients with cancer. Drugs. 2004; 64:323-346.
17. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol. 2001; 19:2865-2874.
18. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF. Phase III, randomized, double-blind study of epoetin α compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005; 23:2606-2617.
19. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; Epoetin β Hematology Study Group. Randomized, doubleblind, placebo-controlled trial of recombinant human erythropoietin, epoetin β, in hematologic malignancies. J Clin Oncol. 2002; 20:2486-2494.
20. Gupta S, Singh PK, Bisth SS, Bhatt ML, Pant M, Gupta R, Singh S, Negi MP. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated by chemoradiotherapy. Cancer Biol Ther. 2009; 8:13-17.
21. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin β is highly effective in treating anemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003; 122:386-393.
22. Coiffer B. Rapid response with epoetin β (NeoRecormon) once weekly or three times weekly in anemic patients with lymphoid malignancies. Blood. 2003; 102:18b-19b, abstract 3775.
23. World Health Organization (WHO). Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). World Health Organization, Geneva, Switzerland, 1979.
24. National Cancer Institute. Guidelines for Reporting Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA, 1978.
25. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed., Lawrence Erlbaum Associates, Hillsdale, NJ, USA, 1988.
26. Demetri GD. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer. 2001; 84 (Suppl 1):31-37.